Nintedanib Esylate
FDA-approved product (capsule, oral), marketed as Nintedanib Esylate, Ofev.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Idiopathic pulmonary fibrosis
- Interstitial pneumonitis
- Non-small cell lung carcinoma
- Systemic scleroderma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other protein kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nintedanib Esylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07583589 · start 2026-05-12
Registered record
- Registry ID
- NCT07583589
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Nintedanib,Dextromethorphan; Nintedanib,Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-05-12
- Completion
- 2027-06-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary Fibrosis (IPF)InterventionNintedanib,Dextromethorphan; Nintedanib,PlaceboPhasePhase 2Registry statusNot yet recruitingA Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
NCT07485920 · start 2026-05-01
Registered record
- Registry ID
- NCT07485920
- Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- Tislelizumab and nintedanib
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-05-01
- Completion
- 2030-01-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLimited-stage Small Cell Lung Cancer (LS-SCLC)InterventionTislelizumab and nintedanibPhasePhase 4Registry statusNot yet recruitingA Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
NCT07454291 · start 2026-04-28
Registered record
- Registry ID
- NCT07454291
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- taladegib; nintedanib; pirfenidone; pirfenidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2026-04-28
- Completion
- 2026-10
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary FibrosisInterventiontaladegib; nintedanib; pirfenidone; pirfenidonePhasePhase 1Registry statusRecruitingIntravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT07299695 · start 2026-01-25
Registered record
- Registry ID
- NCT07299695
- Conditions
- Idiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
- Interventions
- Intravenous immunoglobulin (IVIG); Usual treatment
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2026-01-25
- Completion
- 2028-12
- Enrolment
- 196
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary FibrosisInterventionIntravenous immunoglobulin (IVIG); Usual treatmentPhasePhase 3Registry statusRecruitingNintedanib for Improving Reproductive Outcomes in Adenomyosis
NCT07162961 · start 2025-09-01
Registered record
- Registry ID
- NCT07162961
- Conditions
- Adenomyosis of Uterus
- Interventions
- Nintedanib; Progesterone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Not yet recruiting
- Start
- 2025-09-01
- Completion
- 2027-06-30
- Enrolment
- 328
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenomyosis of UterusInterventionNintedanib; ProgesteronePhasePhase 3Registry statusNot yet recruitingA Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
NCT07080125 · start 2025-06-17
Registered record
- Registry ID
- NCT07080125
- Conditions
- Interstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung Disease
- Interventions
- Ofev®
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Active not recruiting
- Start
- 2025-06-17
- Completion
- 2033-12-31
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInterstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung DiseaseInterventionOfev®PhaseNot recordedRegistry statusActive not recruitingNintedanib Treatment in Unicentric Castleman Disease
NCT06643091 · start 2024-11-01
Registered record
- Registry ID
- NCT06643091
- Conditions
- Castleman Disease
- Interventions
- Nintedanib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2024-11-01
- Completion
- 2030-09-01
- Enrolment
- 13
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastleman DiseaseInterventionNintedanibPhasePhase 2Registry statusNot yet recruitingNintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC
NCT06570317 · start 2024-08-24
Registered record
- Registry ID
- NCT06570317
- Conditions
- NSCLC; Nintedanib; Radiation Pneumonitis
- Interventions
- Nintedanib
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2024-08-24
- Completion
- 2026-06-30
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNSCLC; Nintedanib; Radiation PneumonitisInterventionNintedanibPhaseNot recordedRegistry statusUnknownA Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
NCT06482190 · start 2024-07-11
Registered record
- Registry ID
- NCT06482190
- Conditions
- Idiopathic Pulmonary Fibrosis; Lung; Disease, Interstitial, With Fibrosis
- Interventions
- RSN0402 Part 1; RSN0402 Part 2; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2024-07-11
- Completion
- 2025-02-10
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary Fibrosis; Lung; Disease, Interstitial, With FibrosisInterventionRSN0402 Part 1; RSN0402 Part 2; PlaceboPhasePhase 1Registry statusUnknownProspective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions
NCT05635071 · start 2023-12-01
Registered record
- Registry ID
- NCT05635071
- Conditions
- Uterine Adhesions
- Interventions
- Nintedanib 100 MG [Ofev]; Nintedanib 150 MG [Ofev]
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Unknown
- Start
- 2023-12-01
- Completion
- 2024-12-30
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUterine AdhesionsInterventionNintedanib 100 MG [Ofev]; Nintedanib 150 MG [Ofev]PhasePhase 2 / Phase 3Registry statusUnknownFaecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis
NCT05755308 · start 2023-10
Registered record
- Registry ID
- NCT05755308
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Autologous FMT; Placebo FMT
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-10
- Completion
- 2026-04
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary FibrosisInterventionAutologous FMT; Placebo FMTPhaseNot applicableRegistry statusUnknownStudy of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918 · start 2023-08-24
Registered record
- Registry ID
- NCT05195918
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg + Nintedanib; EGCG 300 mg + Pirfenidone; Placebo 2 capsules + Nintedanib or Pirfenidone; EGCG 600 mg + Nintedanib; EGCG 600 mg + Pirfenidone; Placebo 4 capsules + Nintedanib or Pirfenidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2023-08-24
- Completion
- 2026-03-19
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Pulmonary FibrosisInterventionEGCG 300 mg + Nintedanib; EGCG 300 mg + Pirfenidone; Placebo 2 capsules + Nintedanib or Pirfenidone; EGCG 600 mg + Nintedanib +2 morePhasePhase 1Registry statusCompletedDiarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib
NCT06714812 · start 2023-08-20
Registered record
- Registry ID
- NCT06714812
- Conditions
- IPF
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Active not recruiting
- Start
- 2023-08-20
- Completion
- 2025-12-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIPFInterventionNot recordedPhaseNot recordedRegistry statusActive not recruitingTolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
NCT05335278 · start 2021-06-01
Registered record
- Registry ID
- NCT05335278
- Conditions
- Interstitial Lung Disease; Myopathy, Inflammatory
- Interventions
- Nintedanib 150 milligrams [Ofev]
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2021-06-01
- Completion
- 2025-04-30
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInterstitial Lung Disease; Myopathy, InflammatoryInterventionNintedanib 150 milligrams [Ofev]PhaseNot applicableRegistry statusTerminatedINREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
NCT04702893 · start 2021-05-28
Registered record
- Registry ID
- NCT04702893
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2021-05-28
- Completion
- 2024-04-09
- Enrolment
- 108
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung Diseases, InterstitialInterventionNintedanibPhaseNot recordedRegistry statusCompleted